Babraham Bioscience Technologies’ Technology Development Laboratory moves to Abzena
This settlement permits a seamless transition of present tasks, along with the capabilities, sources and experience from the TDL to Abzena. These capabilities embody enzymatic assay growth, small molecule inhibitor screening, molecular biology, cell tradition and protein purification. These capabilities will complement and combine into Abzena’s present broad vary of options, together with antibody engineering, bioassay and bioanalytical companies and cell line growth to allow the progress of biopharmaceutical analysis from discovery via to manufacturing for scientific trials.
Abzena will even develop on TDL’s present antibody discovery capabilities to provides its shoppers a platform for the speedy era of hybridoma cell strains expressing excessive affinity antibodies to their chosen goal.
Campbell Bunce, SVP Scientific Operations, Abzena mentioned: “Bringing the expertise of the TDL scientists into Abzena and integrating them into our offering across biology and biomanufacturing aligns very well with our services and technologies as a solution provider for drug developers and augments the overall toolbox we can offer our customers. We look forward to building on the knowledge that the TDL team has brought and continuing an excellent working relationship with their current partners.”
Derek Jones, CEO, Babraham Bioscience Technologies mentioned: “We have had a long tradition in supplying this expertise from the TDL, but have experienced challenges in scaling up the services to provide an end-to-end solution to our customer base. We are pleased that these skills and expertise will be utilised and expanded by Abzena, particularly given that the capability will remain available at the Babraham Research Campus, as well as to the wider customer base.”
Abzena (AIM: ABZA) gives proprietary applied sciences and complementary companies to allow the event and manufacture of biopharmaceutical merchandise.
The time period ‘ABZENA Inside’ is utilized by Abzena to describe merchandise which were created utilizing its proprietary applied sciences and are being developed by its companions, and embody Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence charges, milestone funds and/or royalties on ‘ABZENA Inside’ merchandise.
Abzena provides the next companies and applied sciences throughout its principal websites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):
- Immunology analysis research, together with immunogenicity evaluation of candidate biopharmaceutical merchandise;
- Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
- Cell line growth for the manufacture of recombinant proteins and antibodies;
- Contract course of growth and GMP manufacture of biopharmaceuticals, together with monoclonal antibodies and recombinant proteins for preclinical and scientific research;
- Contract artificial chemistry and bioconjugation analysis companies, targeted on antibody-drug conjugates (ADCs);
- Proprietary site-specific conjugation applied sciences and novel payloads for ADC growth; and
- GMP producer of ADC linkers, payloads & mixed linker-payloads.
For extra info, please see www.abzena.com
Fuel Poverty Awareness Day – a helping hand for Cambridge residents
Around four million UK households are in gasoline poverty and are unable to afford toRead More
New Arm Mbed IoT Device Platform capabilities enable companies to get more from their data
Dipesh Patel, President IoT Services Group, Arm, writes: But to transfer from exploring to implementingRead More